25.5.2021 15:37:33 CEST | Aqua Bio Technology ASA | Total number of voting
rights and capital
Reference is made to the stock exchange announcement of Aqua Bio Technology
("ABT" or the "Company") on 29 April 2021 regarding board approval of new shares
in a completed private placement raising gross proceeds of approximately NOK 15
million (the "Private Placement"). In connection with the Private Placement,
shareholder Kjeveortoped Espen Dahl AS lent out 605,017 shares in order to
arrange for settlement of the new shares to be delivered in the Private
Placement.
The share capital increase pertaining to the issuance of the new shares to
settle the share lending agreement with shareholder Kjeveortoped Espen Dahl AS
has today been registered with the Norwegian Register of Business Enterprises
(Nw. Foretaksregisteret). The share capital increase pertaining to the remaining
698,690 shares issued in the Private Placement is still pending registration.
ABT's new share capital is NOK 47,510,970, divided into 19,004,388 shares, each
with a nominal value of NOK 2.50.
The new shares issued in the Private Placement will initially be issued on a
separate ISIN, and will only be converted to the ordinary ISIN of the Company's
shares following approval and publication of a listing prospectus.
For further information, please contact Espen Kvale, CEO, telephone +47 9162
8092.
* * *
Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. ABT's focus on commercialization and development of natural
ingredients and natural skin care products has been, and will continue to be, an
important part of the Company's strategy going forward. ABT is listed on the
Euronext Expand market of the Oslo Stock Exchange.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
DISCLOSURE REGULATION
This information is subject of the disclosure requirements pursuant to section
of 5-12 of the Norwegian Securities Trading Act.
CONTACTS
* Espen Kvale, CEO, +47 916 28 092, espen.kvale@aquabiotech.no
ABOUT AQUA BIO TECHNOLOGY ASA
Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. Aqua Bio Technology is listed on Euronext Expand.
Recent Comments